- The Washington Times - Wednesday, April 1, 2009

SILVER SPRING, MD. (AP) - Government experts say a potential blockbuster diabetes drug from Bristol-Myers Squibb does not carry heart problems seen with similar treatments in recent years.

Bristol-Myers and partner AstraZeneca have asked the Food and Drug Administration to approve their drug Onglyza for millions of Americans with type 2 diabetes. The FDA panel voted 10 to 2 that the companies’ data rule out the risk that the drug hastens heart attack, stroke and other problems.

The drug is the first to go before the panel of diabetes experts since the agency issued new safety guidelines for diabetes treatments. The recommendation is reassuring to a slew of drugmakers working on treatments to compete in the $5 billion U.S. diabetes drug market.



Click to Read More

Click to Hide